BBLG Bone Biologics Corp - Common Stock

NASDAQ · Biotechnology
$0.63
Price · Aug 19, 2026

BBLG Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

Price
$0.63
Market Cap
P/E (TTM)
EPS (TTM)
Revenue (TTM)
Div Yield
ROE
Debt/Equity
52W Range
$1 – $4

BBLG Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

10-Year Performance Revenue, net income, margins and EPS trends

Revenue & Net Income
EPS
Free Cash Flow
Margins

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric
5Y trend
BBLG
Peer Median

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Metric
5Y trend
BBLG
Peer Median

Financial Health Debt, liquidity, solvency — balance sheet strength

Metric
5Y trend
BBLG
Peer Median

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Metric
5Y trend
BBLG
Peer Median

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Metric
5Y trend
BBLG
Peer Median

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

Metric
5Y trend
BBLG
Peer Median

BBLG Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

BUY 7 analysts
  • Strong Buy 2 28.6%
  • Buy 4 57.1%
  • Hold 1 14.3%
  • Sell 0 0.0%
  • Strong Sell 0 0.0%

12-Month Price Target

1 analysts · 2026-08-17
Median target $12.20 +1836.5%
Mean target $12.20 +1836.5%

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

Avg Surprise
0.30%
Period EPS Actual EPS Est Surprise
March 31, 2026 $-0.43 $-0.55 0.12%
Dec. 31, 2025 $-0.14 $-0.35 0.21%
Sept. 30, 2025 $-0.37 $-1.25 0.88%
June 30, 2025 $-1.33 $-0.59 -0.74%
March 31, 2025 $-1.92 $-2.94 1.0%

My Metrics Your personal watchlist — selected rows from Full Fundamentals

📊

Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Institutional owners (13F) 4 filers · $36K total · As of June 30, 2026

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
1 (+1 vs prior Q) 1 (-2 vs prior Q) 0 (-1 vs prior Q) 1 (0 vs prior Q) +22K

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
CITADEL ADVISORS LLC $32,714 23,879 90.22% Shares
Tower Research Capital LLC (TRC) $2,676 1,953 7.38% Shares
CLEAR STREET LLC $556 138 1.53% Shares
SBI Securities Co., Ltd. $315 230 0.87% Shares

Company insiders 14 insiders · 5 officers · 10 directors

Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Stephen R. La Neve CEO and President Dec. 28, 2015 A 0 0 $0
Deina H Walsh Chief Financial Officer Dec. 28, 2015 A 0 0 $0
Amir F Heshmatpour President and Secretary Aug. 7, 2008 J 5,000,000 0 0 $0
Jeff Frelick Chief Operating Officer Dec. 28, 2015 A 0 0 $0
William Jay Treat Chief Technology Officer Dec. 28, 2015 A 0 0 $0
John J Booth Director Dec. 31, 2015 G 20,822 0 0 $0
Steve B Warnecke Director Dec. 31, 2015 G 0 0 0 $0
Benjamin Wu Director Dec. 28, 2015 A 973,628 0 0 $0
George A Oram Director Dec. 28, 2015 A 40,822 0 0 $0
William F Coffin Director Dec. 28, 2015 A 40,822 0 0 $0
Chia B Soo Director Dec. 28, 2015 A 2,988,078 0 0 $0
Jim Delshad Director Dec. 28, 2015 A 40,822 0 0 $0
MUSCULOSKELETAL TRANSPLANT FOUNDATION, INC. Director Oct. 8, 2015 A 973,628 0 0 $0
AFH Holding & Advisory, LLC Aug. 6, 2014 J 4,400,000 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

Activists & 5%+ owners 3 positions

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
Don Hankey, Knight Insurance Company, Ltd. ×9 filings March 29, 2023 Initial filing SEC
Amir Farrokh Heshmatpour, AFH Holding & Advisory, LLC Aug. 8, 2008 Initial filing Passive investment SEC
Amir Farrokh Heshmatpour 2) April 8, 2008 Initial filing SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.